Nutriband Inc. Advances in Opioid Safety with AVERSA(TM) Fentanyl Milestone
Nutriband Inc. achieves a significant milestone in the development of AVERSA(TM) Fentanyl, an abuse-deterrent opioid, marking progress in addressing the global opioid crisis.
Nutriband Inc. (NASDAQ: NTRB) has reached a pivotal moment in the development of AVERSA(TM) Fentanyl, completing commercial-scale manufacturing in collaboration with Kindeva Drug Delivery. This step is crucial for the drug's path to FDA approval, offering a potential solution to the opioid crisis by introducing an abuse-deterrent technology. The opioid epidemic remains a critical public health issue, with synthetic opioids like fentanyl at the center due to their high abuse potential. AVERSA(TM) Fentanyl's development is timely, as it aims to provide a safer alternative for pain management, protected by international patents.
An updated analyst report has raised Nutriband's price target to $15.00, maintaining an Outperform rating, reflecting confidence in the company's trial pathway and execution. Additionally, Nutriband's inclusion in four key indexes, including the Russel Indexes, enhances its profile and credibility in the biotech sector. The company's progress with AVERSA(TM) Fentanyl represents a significant advancement in the quest for safer opioid formulations, addressing an unmet need in global pain management strategies.
For more information on Nutriband Inc. and its developments, visit https://ibn.fm/NTRB.